Mosby's 2014 Nursing Drug Reference (252 page)

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

maraviroc (Rx)

(mah-rav′er-rock)

Selzentry

Func. class.:
Antiretroviral

Chem. class.:
Fusion inhibitor, CCR5-receptor antagonist

ACTION:

Interferes with entry into HIV-1 by inhibiting the fusion of the virus and the cell membrane

USES:

CCR5-tropic HIV in combination with other antiretroviral agents for treating experienced patients

CONTRAINDICATIONS:

Hypersensitivity, dialysis, renal impairment

Precautions:
Pregnancy (B), Asian patients, breastfeeding, renal/hepatic/cardiac disease, electrolyte imbalance, dehydration, immune reconstitution syndrome, infection, MI, orthostatic hypotension, children, geriatric patients, Graves’ disease, Guillain-Barré syndrome, polymyositis

 

Black Box Warning:

Hepatitis, fever, serious rash

DOSAGE AND ROUTES
Calculator
Those not taking any CYP3A inducers/inhibitors

• Adult/adolescent ≥16 yr:
PO
300 mg bid

Those taking CYP3A4 inhibitors with/without a CYP3A inducer

• Adult/adolescent ≥16 yr:
PO
150 mg bid

Those taking CYP3A4 inducers without a strong CYP3A inhibitor

• Adult/adolescent ≥16 yr:
PO
600 mg bid

Renal dose

• Adult:
PO
≤30 ml/min, reduce dose to 150 mg bid

Available forms:
Tabs 150, 300 mg

Administer:

• 
May give without regard to meals, with 8 oz water; swallow whole, do not crush, chew, break

SIDE EFFECTS

CV:
MI, cardiac ischemia, orthostatic hypotension

CNS:
Dizziness, depression,
viral meningitis,
disturbances in consciousness, peripheral neuropathy, paresthesia, dysesthesia, fever

EENT:
Gingival hyperplasia

GI:
Diarrhea, constipation, dyspepsia,
pseudomembranous colitis, hepatotoxicity

INTEG:
Rash, urticaria, pruritus, folliculitis

MS:
Joint pain, leg pain, muscle cramps

RESP:
Cough, upper respiratory tract infection, sinusitis, bronchitis, pneumonia,
bronchospasm, obstruction

SYST:
Herpes virus

PHARMACOKINETICS

Metabolized by P450 system; CYP3A metabolism; excreted 20% urine, 76% feces; protein binding 76%; terminal half-life 14-18 hr

INTERACTIONS

Increase:
maraviroc levels—CYP3A inhibitors (amiodarone, aprepitant, chloramphenicol, clarithromycin, conivaptan, cycloSPORINE, dalfopristin, danazol, diltiazem, erythromycin, estradiol, fluconazole, fluvoxaMINE, imatinib, isoniazid, itraconazole, ketoconazole, miconazole, nefazodone, niCARdipine, propoxyphene, RU-486, tamoxifen, telithromycin, troleandomycin, verapamil, voriconazole, zafirlukast); reduce dose

Decrease:
maraviroc levels—CYP3A4 inducers (efavirenz, aminoglutethimide, barbiturates, bexaroten, bosentan, carBAMazepine, dexamethasone, griseofulvin, modafinil, nafcillin, OXcarbazepine, phenytoin, fosphenytoin, rifabutin, rifampin, rifapentine, topiramate, tipranavir); increase dose

Drug/Herb

• 
Decreased maraviroc effect: St. John’s wort

Drug/Food

• 
High-fat meal decreases absorption 33%

NURSING CONSIDERATIONS
Assess:

• 
HIV:
CD
4
, T-cell count, plasma HIV RNA, CCR5-tropic HIV-1; assess for changes in symptoms, other infections during treatment

• 
Renal studies: serum creatinine

• 
Bowel pattern before, during treatment

• 
Allergies:
skin eruptions: rash, urticaria, itching; discontinue product

 

Black Box Warning:

Hepatitis:
dark urine; abdominal pain, vomiting; yellowing of skin, eyes; hepatomegaly; discontinue product; monitor liver function tests

Perform/provide:

• 
Storage at room temp

Evaluate:

• 
Therapeutic response: improvement in CD4, viral load, T-cell count

Teach patient/family:

• 
To take as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose; that product does not cure condition, should not be shared with others

• 
That product does not cure infection, just controls symptoms and does not prevent infecting others

 
To report sore throat, fever, fatigue
(may indicate superinfection);
yellow skin/eyes, abdominal pain, vomiting
(hepatitis);
itching, SOB
(allergic reaction)

• 
That product must be taken in equal intervals around the clock to maintain blood levels for duration of therapy

• 
To avoid all OTC products unless approved by prescriber

• 
To avoid driving, other hazardous activities until reaction is known; that dizziness may occur

• 
To make position changes slowly to prevent postural hypotension

• 
To notify prescriber if pregnancy is planned or suspected,
not to breastfeed

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

mebendazole (Rx)

(me-ben′da-zole)

Func. class.:
Anthelmintic

Chem. Class.:
Carbamate

ACTION:

Inhibits glucose uptake, degeneration of cytoplasmic microtubules in the cell; interferes with absorption, secretory function

USES:

Pinworms, roundworms, hookworms, whipworms, thread-worms, pork tapeworms, dwarf tapeworms, beef tapeworms, hydatid cyst

CONTRAINDICATIONS:

Hypersensitivity

Precautions:
Pregnancy (C) (1st trimester), breastfeeding, children <2yr, Crohn’s disease, hepatic disease, inflammatory bowel disease, ulcerative colitis

DOSAGE AND ROUTES
Calculator

• Adult and child >2 yr:
PO
100 mg as a single dose (pinworms) or bid ×3 days (whipworms, roundworms, or hookworms); course may be repeated in 3 wk if needed, max 200 mg/day

Available forms:
Chew tabs 100 mg

Administer:

• 
May be crushed, chewed, swallowed whole, mixed with food

• 
PO after meals to avoid GI symptoms

• 
Second course after 3 wk if needed; usually recommended

SIDE EFFECTS

CNS:
Dizziness, fever, headache,
seizures (rare)

GI:
Transient diarrhea, abdominal pain, nausea, vomiting, constipation, hepatitis

INTEG:
Rash

PHARMACOKINETICS
PO

Peak ½-7 hr; excreted in feces primarily (metabolites), small amount in urine (unchanged); highly bound to plasma proteins 95%

INTERACTIONS

Decrease:
mebendazole effect—carBAMazepine, hydantoins

Drug/Food

Increase:
absorption—high-fat meal

NURSING CONSIDERATIONS
Assess:

• 
Stools during entire treatment; specimens must be sent to lab while still warm, also 1-3 wk after treatment is completed

• 
For allergic reaction: rash (rare)

• 
For diarrhea during expulsion of worms; avoid self-contamination with patient’s feces

• 
For infection in other family members, since infection from person to person is common

• 
Blood studies: AST, ALT, alk phos, BUN, CBC during treatment

Perform/provide:

• 
Storage in tight container

Evaluate:

• 
Therapeutic response: expulsion of worms and 3 negative stool cultures after completion of treatment

Teach patient/family:

• 
Proper hygiene after BM, including hand-washing technique; tell patient to avoid putting fingers in mouth; clean fingernails

• 
That infected person should sleep alone; do not shake bed linen, change bed linen daily, wash in hot water, change and wash undergarments daily

• 
To clean toilet daily with disinfectant (green soap solution)

• 
The need for compliance with dosage schedule, duration of treatment

• 
To wear shoes, wash all fruits and vegetables well before eating; use commercial fruit/vegetable cleaner

• 
That all members of the family should be treated (pinworms)

• 
To report jaundice, liver pain

Other books

Forgotten Prophecies by Robert Coleman
Letters to Brendan by Ashley Bloom
El último Dickens by Matthew Pearl
Collapse Depth by Todd Tucker
Curse of the Gypsy by Donna Lea Simpson
The Last Days by Laurent Seksik
Feral Sins by Suzanne Wright
Ramage's Diamond by Dudley Pope